|
|
 |
|
 |
| Test Name: | HBV Drug Resistant Mutation Detection |
| Compliance: | LDT |
| Test Description: | Treatment of chronic hepatitis B (CHB) is geared to achieving sustained suppression of hepatitis B virus (HBV) replication and remission of liver disease, with the aim of preventing liver failure, cirrhosis, and hepatocellular carcinoma. Several drugs have been approved for treatment, including interferon-alfa, peginterferon alfa-2, and the nucleotide/nucleoside analogs (NAs) lamivudine (3TC), adefovir dipivoxil (ADV), entecavir (ETV), telbivudine (LdT), and tenofovir (TDF). Mutations in the HBV genome, and the HBV genotype itself, may affect treatment response and disease course. Treatment with NAs can lead to prolonged viral suppression (loss of HBV DNA, antigen seroconversion, and, rarely, HBsAg loss and HBsAb appearance) in patients with HBV infection. However, prolonged therapy may select for mutations in the HBV DNA polymerase gene (including M204V in the YMDD motif), leading to drug resistance. The rate of acquired resistance varies with the NA used and baseline viral load, among other factors. |
| Methodology: | PCR-Sanger sequencing of HBV polymerase gene |
| Gene Name: | HBV |
| Protein Name: | |
| Specimen Requirements: | EDTA Blood (5mL) |
| Storage Condition: | Ambient Temperature / 4℃ (if overnight is needed) |
| Turn Around Time: | 5 working days from day of specimen received |
| OMIM: | |
| Genetic Home Reference: | |
|
|
|
|
|
|
|
|
Shipping & Billing Information
|
Non-disclosure and Complaints
All data/information generated from within/related to HKMPDC and our customers are treated in strict confidence in accordance with the Personal Data (Privacy) Ordinance of Hong Kong. If you have a complaint, please contact us at the (852) 2986 1213 or email us at contact@hk-mpdc.com. All communications with HKMPDC would be dealt with in strict confidence.
Notice of Privacy Practices
This notice describes how medical information about you may be used and disclosed.
Personal health information or related information released to HKMPDC relating to the services requested may be subjected to re-disclosure by HKMPDC to health care providers, such as doctors, nurses, and others involved in the delivery of the services.
We may also disclose medical information about you to authorised public health or government officials for public health activities as required by law and accreditation body.
Copyright © 2013 香港分子病理檢驗中心 Hong Kong Molecular Pathology Diagnostic Centre Limited (HKMPDC). All Rights Reserved.
Information Updated 1 July, 2023.
|
|
|
|
